SCHEMBL4471125

SCHEMBL4471125

CCc1ccccc1NS(=O)(=O)c1ccc2c(OC(C)=O)cccc2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 6/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 2/20 0.46
SLC16A3 O15427 2/20 0.46
TP53 P04637 3/20 0.44
MAPT P10636 2/20 0.44
ALOX12 P18054 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CASP6 P55212 1/20 0.43
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
OGT O15294 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480492 0.83 CYP2C9 (0.53) LMNAMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4493036 0.82 ALDH1A1 (0.52) LMNANPSR1HTTMEN1KMT2A
SCHEMBL4479458 0.80 CA2 (0.45) HTTMEN1KMT2APOLBALDH1A1
SCHEMBL4482883 0.78 CYP19A1 (0.53) LMNAHTTKMT2APOLBALDH1A1
SCHEMBL4471119 0.76 AKR1C3 (0.53) LMNANPSR1MEN1KMT2APOLB
SCHEMBL13675023 0.76 KMT2A (0.46) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL7820963 0.76 CASP6 (0.58) MEN1KMT2APOLBALDH1A1TSHR
SCHEMBL4485797 0.76 POLB (0.48) LMNANPSR1HTTMEN1KMT2A
SCHEMBL4474912 0.75 KMT2A (0.45) MEN1KMT2APOLBALDH1A1TSHR
SCHEMBL4482164 0.74 ATM (0.54) LMNAHTTPOLBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 LMNA 941/4885NPSR1 3072/4885HTT 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.